Antibody-based immunotherapy for malignant glioma

Seminars in Oncology

Volumn 41, Issue 4, 2014, Pages 496-510

  Gedeon, Patrick C ^a,b   Riccione, Katherine A ^a,b   Fecci, Peter E ^c   Sampson, John H ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b USA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VIII;

ANTIBODY ENGINEERING; ANTIGEN BINDING; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; DISSOCIATION CONSTANT; DRUG EFFICACY; DRUG SAFETY; EFFECTOR CELL; GLIOBLASTOMA; HEALTH CARE QUALITY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOSTIMULATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; GENETICS; GLIOMA; IMMUNOLOGY; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANIMALS; ANTIBODIES; BRAIN NEOPLASMS; GLIOMA; HUMANS; IMMUNOMODULATION; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84906772288     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2014.06.004     Document Type: Article

References (175)

1. United States Cancer Statistics: National Program of Cancer Registries. 2010. Available from: http://appsnccdcdcgov/uscs/.
2. Estimated Number of New Cancer Cases and Deaths by Sex, US. 2014. Available from: http://wwwcancerorg.
3. P.J. Kelly Stereotactic resection and its limitations in glial neoplasms Stereotact Funct Neurosurg 59 1992 84 91
4. M.D. Walker, S.B. Green, D.P. Byar, E. Alexander Jr., U. Batzdorf, and W.H. Brooks et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery N Engl J Med 303 1980 1323 1329
5. D.A. Reardon, G. Akabani, R.E. Coleman, A.H. Friedman, H.S. Friedman, and J.E. Herndon 2nd et al. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results J Clin Oncol 24 2006 115 122
6. R. Stupp, W.P. Mason, M.J. van den Bent, M. Weller, B. Fisher, and M.J. Taphoorn et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 2005 987 996
7. J.J. Vredenburgh, A. Desjardins, J.E. Herndon 2nd, J. Marcello, D.A. Reardon, and J.A. Quinn et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme J Clin Oncol 25 2007 4722 4729
8. R. Stupp, M.E. Hegi, W.P. Mason, M.J. van den Bent, M.J. Taphoorn, and R.C. Janzer et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 2009 459 466
9. J.P. Imperato, N.A. Paleologos, and N.A. Vick Effects of treatment on long-term survivors with malignant astrocytomas Ann Neurol 28 1990 818 822
10. F.S. Hodi, S.J. ODay, D.F. McDermott, R.W. Weber, J.A. Sosman, and J.B. Haanen et al. Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
11. P.W. Kantoff, C.S. Higano, N.D. Shore, E.R. Berger, E.J. Small, and D.F. Penson et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
12. E.T. Boder, K.S. Midelfort, and K.D. Wittrup Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity Proc Natl Acad Sci U S A 97 2000 10701 10705
13. H.R. Hoogenboom Selecting and screening recombinant antibody libraries Nat Biotechnol 23 2005 1105 1116
14. N. Lonberg Fully human antibodies from transgenic mouse and phage display platforms Curr Opin Immunol 20 2008 450 459
15. R.S. Gaston, M.H. Deierhoi, T. Patterson, E. Prasthofer, B.A. Julian, and W.H. Barber et al. OKT3 first-dose reaction: association with T cell subsets and cytokine release Kidney Int 39 1991 141 148
16. T.T. Hansel, H. Kropshofer, T. Singer, J.A. Mitchell, and A.J. George The safety and side effects of monoclonal antibodies Nat Rev Drug Disc 9 2010 325 338
17. J.C. Reynolds, S. Del Vecchio, H. Sakahara, M.E. Lora, J.A. Carrasquillo, and R.D. Neumann et al. Anti-murine antibody response to mouse monoclonal antibodies: clinical findings and implications Int J Radiat Appl Instr B 16 1989 121 125
18. P.J. Carter Potent antibody therapeutics by design Nat Rev Immunol 6 2006 343 357
19. K. Kuus-Reichel, L.S. Grauer, L.M. Karavodin, C. Knott, M. Krusemeier, and N.E. Kay Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Clin Diagn Lab Immunol 1 1994 365 372
20. M.A. Mascelli, H. Zhou, R. Sweet, J. Getsy, H.M. Davis, and M. Graham et al. Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development J Clin Pharmacol 47 2007 553 565
21. D.K. Male Immunology of brain endothelium and the blood-brain barrier M.W.B. Bradbury, Physiology and pharmacology of the blood-brain barrier 1992 Springer Berlin 397 415
22. J. Lee, C. Lund-Smith, A. Borboa, A.M. Gonzalez, A. Baird, and B.P. Eliceiri Glioma-induced remodeling of the neurovascular unit Brain Res 1288 2009 125 134
23. M.A. Bourdon, R.E. Coleman, R.G. Blasberg, D.R. Groothuis, and D.D. Bigner Monoclonal antibody localization in subcutaneous and intracranial human glioma xenografts: paired-label and imaging analysis Anticancer Res 4 1984 133 140
24. D.E. Bullard, C.J. Adams, R.E. Coleman, and D.D. Bigner In vivo imaging of intracranial human glioma xenografts comparing specific with nonspecific radiolabeled monoclonal antibodies J Neurosurg 64 1986 257 262
25. A.M. Scott, F.T. Lee, N. Tebbutt, R. Herbertson, S.S. Gill, and Z. Liu et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors Proc Natl Acad Sci U S A 104 2007 4071 4076
26. M.R. Zalutsky, R.P. Moseley, H.B. Coakham, R.E. Coleman, and D.D. Bigner Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies Cancer Res 49 1989 2807 2813
27. C. Lengauer, K.W. Kinzler, and B. Vogelstein Genetic instabilities in human cancers Nature 396 1998 643 649
28. K.D. Aldape, K. Ballman, A. Furth, J.C. Buckner, C. Giannini, and P.C. Burger et al. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance J Neuropathol Exp Neurol 63 2004 700 707
29. A.J. Ekstrand, C.D. James, W.K. Cavenee, B. Seliger, R.F. Pettersson, and V.P. Collins Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo Cancer Res 51 1991 2164 2172
30. L. Frederick, X.Y. Wang, G. Eley, and C.D. James Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas Cancer Res 60 2000 1383 1387
31. P.A. Humphrey, A.J. Wong, B. Vogelstein, H.S. Friedman, M.H. Werner, and D.D. Bigner et al. Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts Cancer Res 48 1988 2231 2238
32. N. Sugawa, A.J. Ekstrand, C.D. James, and V.P. Collins Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas Proc Natl Acad Sci U S A 87 1990 8602 8606
33. C.J. Wikstrand, L.P. Hale, S.K. Batra, M.L. Hill, P.A. Humphrey, and S.N. Kurpad et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas Cancer Res 55 1995 3140 3148
34. C.J. Wikstrand, R.E. McLendon, A.H. Friedman, and D.D. Bigner Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII Cancer Res 57 1997 4130 4140
35. A.J. Wong, J.M. Ruppert, S.H. Bigner, C.H. Grzeschik, P.A. Humphrey, and D.S. Bigner et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas Proc Natl Acad Sci U S A 89 1992 2965 2969
36. M.P. Cunningham, S. Essapen, H. Thomas, M. Green, D.P. Lovell, and C. Topham et al. Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer Int J Oncol 27 2005 317 325
37. I.E. Garcia de Palazzo, G.P. Adams, P. Sundareshan, A.J. Wong, J.R. Testa, and D.D. Bigner et al. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas Cancer Res 53 1993 3217 3220
38. H. Ge, X. Gong, and C.K. Tang Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis Int J Cancer 98 2002 357 361
39. D.K. Moscatello, M. Holgado-Madruga, A.K. Godwin, G. Ramirez, G. Gunn, and P.W. Zoltick et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors Cancer Res 55 1995 5536 5539
40. E.O. Olapade-Olaopa, D.K. Moscatello, E.H. MacKay, T. Horsburgh, D.P. Sandhu, and T.R. Terry et al. Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer Br J Cancer 82 2000 186 194
41. J.C. Sok, F.M. Coppelli, S.M. Thomas, M.N. Lango, S. Xi, and J.L. Hunt et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting Clin Cancer Res 12 2006 5064 5073
42. T.A. Libermann, H.R. Nusbaum, N. Razon, R. Kris, I. Lax, and H. Soreq et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin Nature 313 1985 144 147
43. S.H. Bigner, P.A. Humphrey, A.J. Wong, B. Vogelstein, J. Mark, and H.S. Friedman et al. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts Cancer Res 50 1990 8017 8022
44. P.A. Humphrey, A.J. Wong, B. Vogelstein, M.R. Zalutsky, G.N. Fuller, and G.E. Archer et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma Proc Natl Acad Sci U S A 87 1990 4207 4211
45. S.K. Batra, S. Castelino-Prabhu, C.J. Wikstrand, X. Zhu, P.A. Humphrey, and H.S. Friedman et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene Cell Growth Differ 6 1995 1251 1259
46. C.T. Chu, K.D. Everiss, C.J. Wikstrand, S.K. Batra, H.J. Kung, and D.D. Bigner Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII) Biochem J 324 1997 855 861
47. H.S. Huang, M. Nagane, C.K. Klingbeil, H. Lin, R. Nishikawa, and X.D. Ji et al. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling J Biol Chem 272 1997 2927 2935
48. R. Nishikawa, X.D. Ji, R.C. Harmon, C.S. Lazar, G.N. Gill, and W.K. Cavenee et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity Proc Natl Acad Sci U S A 91 1994 7727 7731
49. J.A. Boockvar, D. Kapitonov, G. Kapoor, J. Schouten, G.J. Counelis, and O. Bogler et al. Constitutive EGFR signaling confers a motile phenotype to neural stem cells Mol Cell Neurosci 24 2003 1116 1130
50. M.W. Pedersen, V. Tkach, N. Pedersen, V. Berezin, and H.S. Poulsen Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility Int J Cancer 108 2004 643 653
51. G. Lammering, T.H. Hewit, M. Holmes, K. Valerie, W. Hawkins, and P.S. Lin et al. Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity Clin Cancer Res 10 2004 6732 6743
52. R.B. Montgomery, J. Guzman, D.M. ORourke, and W.L. Stahl Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression J Biol Chem 275 2000 17358 17363
53. M. Nagane, Y. Narita, K. Mishima, A. Levitzki, A.W. Burgess, and W.K. Cavenee et al. Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor J Neurosurg 95 2001 472 479
54. A.B. Heimberger, R. Hlatky, D. Suki, D. Yang, J. Weinberg, and M. Gilbert et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients Clin Cancer Res 11 2005 1462 1466
55. M.M. Inda, R. Bonavia, A. Mukasa, Y. Narita, D.W. Sah, and S. Vandenberg et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma Genes Dev 24 2010 1731 1745
56. K. Al-Nedawi, B. Meehan, J. Micallef, V. Lhotak, L. May, and A. Guha et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells Nat Cell Biol 10 2008 619 624
57. D.R. Emlet, P. Gupta, M. Holgado-Madruga, C.A. Del Vecchio, S.S. Mitra, and S.Y. Han et al. Targeting a glioblastoma cancer stem cell population defined by EGF receptor variant III Cancer Res 74 2014 1238 1249
58. R.A. Morgan, L.A. Johnson, J.L. Davis, Z. Zheng, K.D. Woolard, and E.A. Reap et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma Hum Gene Ther 23 2012 1043 1053
59. P.B. Dirks Cancer: stem cells and brain tumours Nature 444 2006 687 688
60. A.R. Dix, W.H. Brooks, T.L. Roszman, and L.A. Morford Immune defects observed in patients with primary malignant brain tumors J Neuroimmunol 100 1999 216 232
61. M.L. Rossi, J.T. Hughes, M.M. Esiri, H.B. Coakham, and D.B. Brownell Immunohistological study of mononuclear cell infiltrate in malignant gliomas Acta Neuropathol 74 1987 269 277
62. M.E. Dudley, and S.A. Rosenberg Adoptive-cell-transfer therapy for the treatment of patients with cancer Nat Rev Cancer 3 2003 666 675
63. G. Suntharalingam, M.R. Perry, S. Ward, S.J. Brett, A. Castello-Cortes, and M.D. Brunner et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412 N Engl J Med 355 2006 1018 1028
64. P.A. Baeuerle, P. Kufer, and R. Lutterbuse Bispecific antibodies for polyclonal T-cell engagement Curr Opin Mol Ther 5 2003 413 419
65. S. Offner, R. Hofmeister, A. Romaniuk, P. Kufer, and P.A. Baeuerle Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells Mol Immunol 43 2006 763 771
66. M. Mack, R. Gruber, S. Schmidt, G. Riethmuller, and P. Kufer Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity J Immunol 158 1997 3965 3970
67. P. Hoffmann, R. Hofmeister, K. Brischwein, C. Brandl, S. Crommer, and R. Bargou et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct Int J Cancer 115 2005 98 104
68. T. Dreier, G. Lorenczewski, C. Brandl, P. Hoffmann, U. Syring, and F. Hanakam et al. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody Int J Cancer 100 2002 690 697
69. B.D. Choi, P.C. Gedeon, J.E. Herndon 2nd, G.E. Archer, E.A. Reap, and L. Sanchez-Perez et al. Human regulatory t cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody Cancer Immunol Res 1 2013 163 167
70. B.D. Choi, P.C. Gedeon, L. Sanchez-Perez, D.D. Bigner, and J.H. Sampson Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody Oncoimmunology 2 2013 e26757
71. R. Bargou, E. Leo, G. Zugmaier, M. Klinger, M. Goebeler, and S. Knop et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody Science 321 2008 974 977
72. D.G. Maloney, A.J. Grillo-Lopez, D.J. Bodkin, C.A. White, T.M. Liles, and I. Royston et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkins lymphoma J Clin Oncol 15 1997 3266 3274
73. P.C. Gedeon, B.D. Choi, T.R. Hodges, D.A. Mitchell, D.D. Bigner, and J.H. Sampson An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma Exp Rev Clin Pharmacol 6 2013 375 386
74. B.D. Choi, C.T. Kuan, M. Cai, G.E. Archer, D.A. Mitchell, and P.C. Gedeon et al. Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma Proc Natl Acad Sci U S A 110 2013 270 275
75. T. Roszman, L. Elliott, and W. Brooks Modulation of T-cell function by gliomas Immunol Today 12 1991 370 374
76. L.A. Morford, L.H. Elliott, S.L. Carlson, W.H. Brooks, and T.L. Roszman T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors J Immunol 159 1997 4415 4425
77. T.L. Roszman, and W.H. Brooks Immunobiology of primary intracranial tumours. III. Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumours Clin Exp Immunol 39 1980 395 402
78. S. Wintterle, B. Schreiner, M. Mitsdoerffer, D. Schneider, L. Chen, and R. Meyermann et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis Cancer Res 63 2003 7462 7467
79. P.E. Fecci, D.A. Mitchell, J.F. Whitesides, W. Xie, A.H. Friedman, and G.E. Archer et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma Cancer Res 66 2006 3294 3302
80. A. Fontana, H. Hengartner, N. de Tribolet, and E. Weber Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects J Immunol 132 1984 1837 1844
81. M. Wrann, S. Bodmer, R. Demartin, C. Siepl, R. Hoferwarbinek, and K. Frei et al. T-cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth-factor-beta EMBO J 6 1987 1633 1636
82. M.C. Kuppner, M.F. Hamou, Y. Sawamura, S. Bodmer, and N. de Tribolet Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta 2 J Neurosurg 71 1989 211 217
83. M.E. Keir, M.J. Butte, G.J. Freeman, and A.H. Sharpe PD-1 and its ligands in tolerance and immunity Ann Rev Immunol 26 2008 677 704
84. W. Zou, and L. Chen Inhibitory B7-family molecules in the tumour microenvironment Nat Rev Immunol 8 2008 467 477
85. R. Wilmotte, K. Burkhardt, V. Kindler, M.C. Belkouch, G. Dussex, and N. Tribolet et al. B7-homolog 1 expression by human glioma: a new mechanism of immune evasion Neuroreport 16 2005 1081 1085
86. Y. Yao, R. Tao, X.M. Wang, Y. Wang, Y. Mao, and L.F. Zhou B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells Neurooncology 11 2009 757 766
87. B. Wei, L. Wang, X. Zhao, C. Du, Y. Guo, and Z. Sun The upregulation of programmed death 1 on peripheral blood T cells of glioma is correlated with disease progression Tumour Biol 35 2013 2923 2929
88. J. Zeng, A.P. See, J. Phallen, C.M. Jackson, Z. Belcaid, and J. Ruzevick et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas Int J Radiat Oncol Biol Phys 86 2013 343 349
89. K. Hathcock, G. Laszlo, H. Dickler, J. Bradshaw, P. Linsley, and R. Hodes Identification of an alternative CTLA4 ligand costimulatory for T cell activation Science 262 1993 905 907
90. R. Schwartz Costimulation of T lymphocytes: the role of CD28, CTLA4, and B7/BB1 in interleukin2 production and immunotherapy Cell 71 1992 1065 1068
91. J.L. Riley, M. Mao, S. Kobayashi, M. Biery, J. Burchard, and G. Cavet et al. Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors Proc Natl Acad Sci U S A 99 2002 11790 11795
92. R. Parry, J. Chemnitz, K. Frauwirth, A. Lanfranco, I. Braunstein, and S. Kobayashi et al. CTLA4 and PD1 receptors inhibit Tcell activation by distinct mechanisms Mol Cell Biol 25 2005 9543 9553
93. C.Y. Zheng, D.R. Huang, L. Liu, M. Bjorkholm, G. Holm, and Q. Yi et al. Cytotoxic T-lymphocyte antigen-4 microsatellite polymorphism is associated with multiple myeloma Br J Haematol 112 2001 216 218
94. M. Monne, G. Piras, A. Palmas, L. Arru, M. Murineddu, and G. Latte et al. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) gene polymorphism and susceptibility to non-Hodgkins lymphoma Am J Hematol 76 2004 14 18
95. N. Erfani, M. Razmkhah, A.R. Talei, A.M. Pezeshki, M. Doroudchi, and A. Monabati et al. Cytotoxic T lymphocyte antigen-4 promoter variants in breast cancer Cancer Genet Cytogenet 165 2006 114 120
96. M.M. Welsh, K.M. Applebaum, S.K. Spencer, A.E. Perry, M.R. Karagas, and H.H. Nelson CTLA4 variants, UV-induced tolerance, and risk of non-melanoma skin cancer Cancer Res 69 2009 6158 6163
97. Q. Wu, X. Zhan, T. Dou, H. Chen, W. Fan, and K. Zhou et al. CTLA4 A49G Polymorphism shows significant association with glioma risk in a Chinese population Biochem Genet 49 2011 190 201
98. B. Fong, R. Jin, X. Wang, M. Safaee, D.N. Lisiero, and I. Yang et al. Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients PloS One 7 2012 e32614
99. + T cell compartment without affecting regulatory T-cell function Clin Cancer Res 13 2007 2158 2167
100. P. Agarwalla, Z. Barnard, P. Fecci, G. Dranoff, and W.T. Curry Jr Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors J Immunother 35 2012 385 389
101. J.A. Hill, M. Feuerer, K. Tash, S. Haxhinasto, J. Perez, and R. Melamed et al. Foxp3 transcriptionfactordependent and -independent regulation of the regulatory T cell transcriptional signature Immunity 27 2007 786 800
102. M.A. Gavin, J.P. Rasmussen, J.D. Fontenot, V. Vasta, V.C. Manganiello, and J.A. Beavo et al. Foxp3-dependent programme of regulatory T-cell differentiation Nature 445 2007 771 775
103. K. Wing, Y. Onishi, P. Prieto-Martin, T. Yamaguchi, M. Miyara, and Z. Fehervari et al. CTLA4 control over Foxp3 regulatory T cell function Science 322 2008 271 275
104. + T-cell infiltration and hemeoxygenase-1 expression correlate with tumor grade in human gliomas J Neurooncol 2007 145 152
105. + regulatory T cells in human gliomas Clin Cancer Res 14 2008 5166 5172
106. J. Vom Berg, M. Vrohlings, S. Haller, A. Haimovici, P. Kulig, and A. Sledzinska et al. Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection J Exp Med 210 2013 2803 2811
107. + regulatory T cells in mice with experimental brain tumors J Neurosurg 105 2006 430 437
108. M.D. Poirier, H. Haban, and A. El Andaloussi A combination of systemic and intracranial anti-CD25 immunotherapy elicits a long-time survival in murine model of glioma J Oncol 2009 2009 963037
109. O.M. Grauer, S. Nierkens, E. Bennink, L.W.J. Toonen, L. Boon, and P. Wesseling et al. CD4 FoxP3 regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo Int J Cancer 121 2007 95 105
110. C.E. Fadul, J.L. Fisher, J. Gui, T.H. Hampton, A.L. Cote, and M.S. Ernstoff Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme Neurooncology 13 2011 393 400
111. D.A. Mitchell, X. Cui, R.J. Schmittling, L. Sanchez-Perez, D.J. Snyder, and K.L. Congdon et al. Monoclonal antibody blockade of IL-2 receptor alpha during lymphopenia selectively depletes regulatory T cells in mice and humans Blood 118 2011 3003 3012
112. W. Maes, T. Verschuere, A. Van Hoylandt, L. Boon, and S. Van Gool Depletion of regulatory T cells in a mouse experimental glioma model through anti-CD25 treatment results in the infiltration of non-immunosuppressive myeloid cells in the brain Clin Dev Immunol 2013 2013 952469
113. P.C. Gedeon, B.D. Choi, J.H. Sampson, and D.D. Bigner Rindopepimut anti-EGFRvIII peptide vaccine oncolytic Drug Future 38 2013 147 155
114. J.H. Sampson, R.J. Schmittling, G.E. Archer, K.L. Congdon, S.K. Nair, and E.A. Reap et al. A pilot study of IL-2R alpha blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma PloS One 7 2012
115. W. Paulus, I. Baur, C. Huettner, B. Schmausser, W. Roggendorf, and K.H. Schlingensiepen et al. Effects of transforming growth factor-beta 1 on collagen synthesis, integrin expression, adhesion and invasion of glioma cells J Neuropathol Exp Neurol 54 1995 236 244
116. S. Koochekpour, A. Merzak, and G.J. Pilkington Vascular endothelial growth factor production is stimulated by gangliosides and TGF-beta isoforms in human glioma cells in vitro Cancer Lett 102 1996 209 215
117. + regulatory T cells from human peripheral blood J Immunol 166 2001 7282 7289
118. +CD25- T cells through Foxp3 induction and downregulation of Smad7 J Immunol 172 2004 5149 5153
119. +) T regulatory cells: Role of tumor-derived TGF-beta J Immunol 178 2007 2883 2892
120. A. Fontana, K. Frei, S. Bodmer, E. Hofer, M.H. Schreier, and M.A. Palladino Jr. et al. Transforming growth factor-beta inhibits the generation of cytotoxic T cells in virus-infected mice J Immunol 143 1989 3230 3234
121. J.H. Kehrl, L.M. Wakefield, A.B. Roberts, S. Jakowlew, M. Alvarez-Mon, and R. Derynck et al. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth J Exp Med 163 1986 1037 1050
122. R. Ueda, M. Fujita, X. Zhu, K. Sasaki, E.R. Kastenhuber, and G. Kohanbash et al. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines Clin Cancer Res 15 2009 6551 6559
123. P. Hulper, W. Schulz-Schaeffer, C. Dullin, P. Hoffmann, J. Harper, and L. Kurtzberg et al. Tumor localization of an anti-TGF-beta antibody and its effects on gliomas Int J Oncol 38 2011 51 59
124. J.P. Stevenson, H.L. Kindler, E. Papasavvas, J. Sun, M. Jacobs-Small, and J. Hull et al. Immunological effects of the TGFbeta-blocking antibody GC1008 in malignant pleural mesothelioma patients Oncoimmunology 2 2013 e26218
125. A.H. Sharpe Mechanisms of costimulation Immunological reviews 229 2009 5 11
126. E.A. Ranheim, and T.J. Kipps Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal J Exp Med 177 1993 925 935
127. M. Roy, A. Aruffo, J. Ledbetter, P. Linsley, M. Kehry, and R. Noelle Studies on the interdependence of gp39 and B7 expression and function during antigen-specific immune responses Eur J Immunol 25 1995 596 603
128. M. Jenkins, and R. Schwartz Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo J Exp Med 165 1987 302 319
129. S. Nagaraj, and D.I. Gabrilovich Tumor escape mechanism governed by myeloid-derived suppressor cells Cancer Res 68 2008 2561 2563
130. J.M. Green, P.J. Noel, A.I. Sperling, T.L. Walunas, G.S. Gray, and J.A. Bluestone et al. Absence of B7-dependent responses in CD28-deficient mice Immunity 1 1994 501 508
131. S.J. Antonia, J. Seigne, J. Diaz, C. Muro-Cacho, M. Extermann, and M.J. Farmelo et al. Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma J Urol 167 2002 1995 2000
132. M. Fishman, T.B. Hunter, H. Soliman, P. Thompson, M. Dunn, and R. Smilee et al. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma J Immunother 31 2008 72 80
133. L.E. Raez, P.A. Cassileth, J.J. Schlesselman, K. Sridhar, S. Padmanabhan, and E.Z. Fisher et al. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer J Clin Oncol 22 2004 2800 2807
134. H. Horig, D.S. Lee, W. Conkright, J. Divito, H. Hasson, and M. LaMare et al. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 costimulatory molecule Cancer Immunol Immunother 49 2000 504 514
135. M. von Mehren, P. Arlen, K.Y. Tsang, A. Rogatko, N. Meropol, and H.S. Cooper et al. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas Clin Cancer Res 6 2000 2219 2228
136. H.L. Kaufman, H.J. Lenz, J. Marshall, D. Singh, C. Garett, and C. Cripps et al. Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer Clin Cancer Res 14 2008 4843 4849
137. S. Mallett, S. Fossum, and A.N. Barclay Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes - a molecule related to nerve growth factor receptor EMBO J 9 1990 1063 1068
138. D.J. Paterson, W.A. Jefferies, J.R. Green, M.R. Brandon, P. Corthesy, and M. Puklavec et al. Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts Mol Immunol 24 1987 1281 1290
139. K.E. Pollok, Y.J. Kim, Z. Zhou, J. Hurtado, K.K. Kim, and R.T. Pickard et al. Inducible T cell antigen 4-1BB. Analysis of expression and function J Immunol 150 1993 771 781
140. H. Schwarz, J. Valbracht, J. Tuckwell, J. Vonkempis, and Lotz M. Ila the Human 4-1bb homolog, is inducible in lymphoid and other cell lineages Blood 85 1995 1043 1052
141. J. Kjaergaard, J. Tanaka, J.A. Kim, K. Rothchild, A. Weinberg, and S. Shu Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth Cancer Res 60 2000 5514 5521
142. E.W. Newcomb, Y. Lukyanov, N. Kawashima, M. Alonso-Basanta, S.C. Wang, and M. Liu et al. Radiotherapy enhances anti-tumor effect of anti-CD137 therapy in a mouse Glioma model Radiat Res 173 2010 426 432
143. C. Kuhnol, M. Herbarth, J. Foll, M.S. Staege, and C. Kramm CD137 stimulation and p38 MAPK inhibition improve reactivity in an in vitro model of glioblastoma immunotherapy Cancer Immunol Immunother 62 2013 1797 1809
144. K.A. Murphy, M.G. Lechner, F.E. Popescu, J. Bedi, S.A. Decker, and P. Hu et al. An in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomas Clin Cancer Res 18 2012 4657 4668
145. K.E. Smith, S. Janelidze, E. Visse, W. Badn, L. Salford, and P. Siesjo et al. Synergism between GM-CSF and IFN gamma: Enhanced immunotherapy in mice with glioma Int J Cancer 120 2007 75 80
146. S. Fritzell, E. Sanden, S. Eberstal, E. Visse, A. Darabi, and P. Siesjo Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion Cancer Immunol Immunother 62 2013 1463 1474
147. S.D. Park, C.H. Kim, C.K. Kim, J.A. Park, H.J. Sohn, and Y.K. Hong et al. Cross-priming by temozolomide enhances anti-tumor immunity of dendritic cell vaccination in murine brain tumor model Vaccine 25 2007 3485 3491
148. L.A. Emens, and E.M. Jaffee Leveraging the activity of tumor vaccines with cytotoxic chemotherapy Cancer Res 65 2005 8059 8064
149. S.M. OReilly, E.S. Newlands, M.G. Glaser, M. Brampton, J.M. Rice-Edwards, and R.D. Illingworth et al. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours Eur J Cancer 29A 1993 940 942
150. A.D. Weinberg, M.M. Rivera, R. Prell, A. Morris, T. Ramstad, and J.T. Vetto et al. Engagement of the OX-40 receptor in vivo enhances anti-tumor immunity J Immunol 164 2000 2160 2169
151. I. Melero, W.W. Shuford, S.A. Newby, A. Aruffo, J.A. Ledbetter, and K.E. Hellstrom et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors Nat Med 3 1997 682 685
152. D. Hirschhorn-Cymerman, G.A. Rizzuto, T. Merghoub, A.D. Cohen, F. Avogadri, and A.M. Lesokhin et al. OX40 engagement and chemotherapy combination provides potent anti-tumor immunity with concomitant regulatory T cell apoptosis J Exp Med 206 2009 1103 1116
153. + T cell proliferation and lead to the amplification in vivo of
154. M. Sznol, F.S. Hodi, K. Margolin, D.F. McDermott, M.S. Ernstoff, and J.M. Kirkwood et al. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody in patients with advanced cancer J Clin Oncol 26 2008
155. G. Nocentini, and C. Riccardi GITR: a multifaceted regulator of immunity belonging to the tumor necrosis factor receptor superfamily Eur J Immunol 35 2005 1016 1022
156. +) T-cell responses and tumor immunity Cancer Res 66 2006 4904 4912
157. + regulatory T cells J Exp Med 202 2005 885 891
158. + effector T cells in mediating agonistic anti-GITR mAb-induced-immune activation and tumor immunity in CT26 tumors J Immunol 179 2007 7365 7375
159. R.A. van Lier, J. Borst, T.M. Vroom, H. Klein, P. Van Mourik, and W.P. Zeijlemaker et al. Tissue distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen J Immunol 139 1987 1589 1596
160. + T cell tolerance and permits effective immunity Immunity 29 2008 934 946
161. J. Miller, G. Eisele, G. Tabatabai, S. Aulwurm, G. von Kurthy, and L. Stitz et al. Soluble CD70: a novel immunotherapeutic agent for experimental glioblastoma J Neurosurg 113 2010 280 285
162. L.Z. He, N. Prostak, L.J. Thomas, L. Vitale, J. Weidlick, and A. Crocker et al. Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice J Immunol 191 2013 4174 4183
163. S.P. Schoenberger, R.E.M. Toes, E.I.H. van der Voort, R. Offringa, and C.J.M. Melief T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions Nature 393 1998 480 483
164. M.F. Mackey, J.R. Gunn, P.P. Ting, H. Kikutani, G. Dranoff, and R.J. Noelle et al. Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154 Cancer Res 57 1997 2569 2574
165. L. Diehl, A.T. den Boer, S.P. Schoenberger, E.I. van der Voort, T.N. Schumacher, and C.J. Melief et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy Nat Med 5 1999 774 779
166. R.R. French, H.T.C. Chan, A.L. Tutt, and M.J. Glennie CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help Nat Med 5 1999 548 553
167. F.B. Li, and J.V. Ravetch Inhibitory Fc gamma receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies Science 333 2011 1030 1034
168. Y. Zhang, T. Huang, Y. Hu, and Y. Wang Activation of CD40 by soluble recombinant human CD40 ligand inhibits human glioma cells proliferation via nuclear factor-kappaB signaling pathway J Huazhong U Sci Technol Med Sci 32 2012 691 696
169. M. Klinger, C. Brandl, G. Zugmaier, Y. Hijazi, R.C. Bargou, and M.S. Topp et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab Blood 119 2012 6226 6233
170. A. Loffler, M. Gruen, C. Wuchter, F. Schriever, P. Kufer, and T. Dreier et al. Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct Leukemia 17 2003 900 909
171. J.H. Sampson, B.D. Choi, L. Sanchez-Perez, C.M. Suryadevara, D.J. Snyder, and C.T. Flores et al. EGFRvIII mCAR-modified t-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss Clin Cancer Res 20 2014 972 984
172. J.H. Sampson, A.B. Heimberger, G.E. Archer, K.D. Aldape, A.H. Friedman, and H.S. Friedman et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma J Clin Oncol 28 2010 4722 4729
173. O. Hamid, C. Robert, A. Daud, F.S. Hodi, W.J. Hwu, and R. Kefford et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N Engl J Med 369 2013 134 144
174. J.D. Wolchok, H. Kluger, M.K. Callahan, M.A. Postow, N.A. Rizvi, and A.M. Lesokhin et al. Nivolumab plus ipilimumab in advanced melanoma N Engl J Med 369 2013 122 133
175. J.L. Riley Combination checkpoint blockade - taking melanoma immunotherapy to the next level N Engl J Med 369 2013 187 189